Cytek Biosciences, Inc. CTKB Settlement Liabilities (Current)
Settlement Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SettlementLiabilitiesCurrent.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s settlement liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s settlement liabilities (current)?
- Cytek Biosciences, Inc. (CTKB) reported settlement liabilities (current) of $2.21M in Q1 2026.
- How has Cytek Biosciences, Inc.'s settlement liabilities (current) changed year-over-year?
- Cytek Biosciences, Inc.'s settlement liabilities (current) increased by 29.5% year-over-year, from $1.71M to $2.21M.
- What is the long-term trend for Cytek Biosciences, Inc.'s settlement liabilities (current)?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s settlement liabilities (current) has grown at a -16.8% compound annual growth rate (CAGR), from $6.25M to $2.5M.
- What does settlement liabilities (current) mean?
- This metric represents the total value of financial obligations and payables resulting from completed transactions that are contractually due for payment within one year. It serves as a key indicator of short-term liquidity requirements and the company's immediate cash outflow commitments. Monitoring this balance helps investors assess the firm's ability to manage its near-term operational and financial debts without disrupting core business activities.